Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD039
MIFTS: 40

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Adenocarcinoma

About this section

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 73
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 55

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3711
NCIt 50 C39836 C4032
UMLS 73 C0279682
Sources

Summaries for Bladder Adenocarcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to clear cell adenocarcinoma and mucinous adenocarcinoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1), and among its related pathways/superpathways are Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases and Pathways Affected in Adenoid Cystic Carcinoma. The drugs Epirubicin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, colon and kidney, and related phenotype is neoplasm.

Sources

Related Diseases for Bladder Adenocarcinoma

About this section

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 30.3 KRT20 KRT7
2 mucinous adenocarcinoma 29.7 CDX2 KRT20 KRT7
3 signet ring cell adenocarcinoma 29.5 CDX2 KRT20 KRT7
4 glandular cystitis 29.4 CDX2 KRT20 KRT7 UCA1
5 transitional cell carcinoma 29.3 HRAS KRT20 KRT7
6 colorectal adenocarcinoma 28.8 CDX2 CTNNB1 HRAS KRT20 KRT7
7 lung cancer susceptibility 3 28.8 CDX2 CTNNB1 HRAS KRT20 KRT7
8 bladder signet ring cell adenocarcinoma 11.5
9 pelvic lipomatosis 11.2
10 bladder clear cell adenocarcinoma 11.1
11 bladder colloid adenocarcinoma 11.1
12 bladder colonic type adenocarcinoma 11.1
13 bladder urachal adenocarcinoma 11.1
14 bladder tubulo-cystic clear cell adenocarcinoma 11.1
15 bladder papillary clear cell adenocarcinoma 11.1
16 bladder hepatoid adenocarcinoma 11.1
17 adenocarcinoma 10.5
18 hepatoid adenocarcinoma 10.2
19 gallbladder adenoma 10.2 CTNNB1 HRAS
20 goblet cell carcinoid 10.1 CTNNB1 KRT20
21 serous cystadenocarcinoma 10.1 FBXW7 HRAS
22 vaginal benign neoplasm 10.1 CDX2 KRT20
23 vaginal adenoma 10.1 CDX2 KRT20
24 vaginal tubulovillous adenoma 10.1 CDX2 KRT20
25 villous adenoma 10.1 CDX2 KRT20
26 colorectal adenoma 10.0 CTNNB1 HRAS
27 skin benign neoplasm 10.0 HRAS KRT20
28 papillary craniopharyngioma 10.0 CTNNB1 KRT7
29 craniopharyngioma 10.0 CTNNB1 KRT7
30 uterine carcinosarcoma 10.0 CTNNB1 FBXW7 HRAS
31 adenomyoma 10.0 CTNNB1 KRT7
32 female reproductive endometrioid cancer 10.0 CTNNB1 KRT7
33 pulmonary sclerosing hemangioma 10.0 CTNNB1 KRT7
34 sclerosing hemangioma 10.0 CTNNB1 KRT7
35 tubular adenocarcinoma 10.0 CDX2 KRT20
36 ovarian serous cystadenocarcinoma 10.0 FBXW7 HRAS
37 acinar cell carcinoma 10.0 CTNNB1 KRT7
38 cystadenoma 10.0 KRT20 KRT7
39 prostate squamous cell carcinoma 10.0 HRAS KRT7
40 cystic basal cell carcinoma 10.0 KRT20 KRT7
41 seminal vesicle adenocarcinoma 10.0 KRT20 KRT7
42 transverse colon cancer 10.0 KRT20 KRT7
43 malignant syringoma 10.0 KRT20 KRT7
44 papillary transitional carcinoma 10.0 KRT20 KRT7
45 eyelid carcinoma 10.0 KRT20 KRT7
46 krukenberg carcinoma 10.0 KRT20 KRT7
47 linitis plastica 10.0 KRT20 KRT7
48 small cell carcinoma 10.0 KRT20 KRT7
49 small cell carcinoma of the bladder 10.0 KRT20 KRT7
50 adenoid squamous cell carcinoma 10.0 KRT20 KRT7

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma
Sources

Symptoms & Phenotypes for Bladder Adenocarcinoma

About this section

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDX2 CTNNB1 FBXW7 HRAS
Sources

Drugs & Therapeutics for Bladder Adenocarcinoma

About this section

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
3
BCG vaccine Investigational Phase 3
4 Interferon-alpha Phase 3
5 Antiviral Agents Phase 3,Phase 2
6 Adjuvants, Immunologic Phase 3
7 Anti-Bacterial Agents Phase 3
8 Pharmaceutical Solutions Phase 3
9 Immunologic Factors Phase 3,Phase 2,Phase 1
10 Antibiotics, Antitubercular Phase 3
11 Alkylating Agents Phase 3,Phase 2
12 Vaccines Phase 3,Phase 1
13 interferons Phase 3
14 Mitomycins Phase 3
15 Anti-Infective Agents Phase 3,Phase 2,Phase 1
16 Nucleic Acid Synthesis Inhibitors Phase 3
17 Topoisomerase Inhibitors Phase 3,Phase 2
18 Antimetabolites Phase 3,Phase 2
19 Immunosuppressive Agents Phase 3,Phase 2
20 Antimetabolites, Antineoplastic Phase 3,Phase 2
21
leucovorin Approved Phase 2 58-05-9 6006 143
22
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
23
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
24
Ifosfamide Approved Phase 2 3778-73-2 3690
25
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
26
Nivolumab Approved Phase 2,Phase 1 946414-94-4
27
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
28
Gemcitabine Approved Phase 2 95058-81-4 60750
29
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
32
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
33 Piritrexim Investigational Phase 2 72732-56-0
34
Rubitecan Investigational Phase 2 91421-42-0
35
Camptothecin Experimental Phase 2 7689-03-4
36
Tremelimumab Investigational Phase 2 745013-59-6
37 Vitamin B Complex Phase 2
38 Vitamin B9 Phase 2
39 Folic Acid Antagonists Phase 2
40 Folate Phase 2
41 topoisomerase I inhibitors Phase 2
42 Antineoplastic Agents, Alkylating Phase 2
43
Isophosphamide mustard Phase 2 0
44 Albumin-Bound Paclitaxel Phase 2
45 Antineoplastic Agents, Phytogenic Phase 2
46 Antimitotic Agents Phase 2
47 Antibodies Phase 2,Phase 1
48 Immunoglobulins Phase 2,Phase 1
49 Antibodies, Monoclonal Phase 2,Phase 1
50 Micronutrients Phase 2

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
3 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
4 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
5 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
6 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
7 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
8 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting NCT03430895 Phase 2 durvalumab and tremelimumab
9 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
10 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
11 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
12 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
13 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
14 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
15 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
16 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
17 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Sources

Genetic Tests for Bladder Adenocarcinoma

About this section
Sources

Anatomical Context for Bladder Adenocarcinoma

About this section

MalaCards organs/tissues related to Bladder Adenocarcinoma:

41
Lung, Colon, Kidney, Ovary, Prostate, Thymus, Appendix
Sources

Publications for Bladder Adenocarcinoma

About this section

Articles related to Bladder Adenocarcinoma:

(show all 35)
# Title Authors Year
1
Primary bladder adenocarcinoma: Case report with long-term follow-up. ( 29785373 )
2018
2
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. ( 28511402 )
2017
3
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. ( 28548125 )
2017
4
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. ( 27006847 )
2016
5
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. ( 27427223 )
2016
6
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. ( 26955660 )
2016
7
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. ( 27048257 )
2016
8
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. ( 27288750 )
2016
9
Gall bladder Adenocarcinoma in a Young Girl. ( 26139973 )
2015
10
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. ( 26421206 )
2015
11
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. ( 24716732 )
2014
12
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. ( 25040620 )
2014
13
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. ( 24596525 )
2013
14
Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen. ( 24281125 )
2013
15
[Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. ( 23589601 )
2013
16
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. ( 23076693 )
2012
17
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. ( 23121893 )
2012
18
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. ( 22294067 )
2011
19
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. ( 22081531 )
2011
20
Association of bladder adenocarcinoma and BK virus infection in a pancreatico-renal transplant recipient. ( 28657060 )
2010
21
Bladder adenocarcinoma following gastrocystoplasty. ( 20392671 )
2010
22
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. ( 19221283 )
2009
23
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. ( 18604226 )
2008
24
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. ( 18307003 )
2008
25
Urinary bladder adenocarcinoma arising in a spina bifida patient. ( 18022132 )
2007
26
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. ( 15822823 )
2005
27
Spontaneous resolution of bladder adenocarcinoma. ( 15160537 )
2003
28
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. ( 19861819 )
2003
29
Bladder adenocarcinoma: 31 reported cases. ( 11718635 )
2001
30
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. ( 11506474 )
2001
31
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. ( 10510893 )
1999
32
Urine cytology of primary and secondary urinary bladder adenocarcinoma. ( 9915134 )
1998
33
Bladder adenocarcinoma during pregnancy: a case report. ( 8855078 )
1996
34
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. ( 8389497 )
1993
35
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). ( 6983292 )
1982
Sources

Variations for Bladder Adenocarcinoma

About this section
Sources

Expression for Bladder Adenocarcinoma

About this section
Search GEO for disease gene expression data for Bladder Adenocarcinoma.
Sources

Pathways for Bladder Adenocarcinoma

About this section

Pathways related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases 22
Show member pathways
 11.99 CDX2 CTNNB1 HRAS
2
Pathways Affected in Adenoid Cystic Carcinoma 1
11.14 FBXW7 HRAS
3
TGF-beta Receptor Signaling (WikiPathways) 1
10.92 CTNNB1 HRAS
4
Incretin synthesis, secretion, and inactivation 66
Show member pathways
 10.7 CDX2 CTNNB1
5
Extracellular vesicle-mediated signaling in recipient cells 1
10.1 CTNNB1 HRAS
Sources

GO Terms for Bladder Adenocarcinoma

About this section

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vasculogenesis GO:0001570 9.16 CTNNB1 FBXW7
2 negative regulation of gene expression GO:0010629 9.13 CTNNB1 FBXW7 HRAS
3 vasculature development GO:0001944 8.62 CTNNB1 FBXW7
Sources

Sources for Bladder Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....